These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 2133845)
41. Vascular rejection post heart transplantation is associated with positive flow cytometric cross-matching. McCarthy JF; Cook DJ; Massad MG; Sano Y; O'Malley KJ; Ratliff NR; Stewart RW; Smedira NG; Starling RC; Young JB; McCarthy PM Eur J Cardiothorac Surg; 1998 Aug; 14(2):197-200. PubMed ID: 9755007 [TBL] [Abstract][Full Text] [Related]
42. Histocompatibility and other risk factors for histological rejection of human cardiac allografts during the first three months following transplantation. Zerbe TR; Arena VC; Kormos RL; Griffith BP; Hardesty RL; Duquesnoy RJ Transplantation; 1991 Sep; 52(3):485-90. PubMed ID: 1897021 [TBL] [Abstract][Full Text] [Related]
44. Evidence for an accelerated rejection response to cardiac allografts in antigen-treated mice which then resolves. Superina RA; Wood KJ; Millard P; Morris PJ Transplant Proc; 1987 Feb; 19(1 Pt 2):1056-7. PubMed ID: 3274273 [No Abstract] [Full Text] [Related]
45. Human leukocyte antigen compatibility in heart transplantation: evidence for a differential role of HLA matching on short- and medium-term patient survival. Taylor CJ; Smith SI; Sharples LD; Parameshwar J; Cary NR; Keogan M; Wallwork J; Large SR Transplantation; 1997 May; 63(9):1346-51. PubMed ID: 9158031 [TBL] [Abstract][Full Text] [Related]
46. Controversies in defining cardiac antibody-mediated rejection: need for updated criteria. Kfoury AG; Hammond ME J Heart Lung Transplant; 2010 Apr; 29(4):389-94. PubMed ID: 20189413 [TBL] [Abstract][Full Text] [Related]
47. Histocompatibility and other rejection risk factors in cardiac transplantation. Zerbe TR; Kormos R; Arena V; Griffith B; Hardesty R; Duquesnoy R Transplant Proc; 1991 Feb; 23(1 Pt 2):1155-6. PubMed ID: 1989176 [No Abstract] [Full Text] [Related]
48. Multi-organ transplantation: is there a protective effect against acute and chronic rejection? Pinderski LJ; Kirklin JK; McGiffin D; Brown R; Naftel DC; Young KR; Smith K; Bourge RC; Tallaj JA; Rayburn BK; Benza R; Zorn G; Leon K; Wille K; Deierhoi M; George JF J Heart Lung Transplant; 2005 Nov; 24(11):1828-33. PubMed ID: 16297789 [TBL] [Abstract][Full Text] [Related]
49. Clinical orthotopic cardiac transplantation. Slater AD; Klein JB; Gray LA Am J Surg; 1987 Jun; 153(6):582-93. PubMed ID: 3296808 [TBL] [Abstract][Full Text] [Related]
50. Reduction of cellular rejection and increase in longer-term survival after heart transplantation after HLA-DR matching. Smith JD; Rose ML; Pomerance A; Burke M; Yacoub MH Lancet; 1995 Nov; 346(8986):1318-22. PubMed ID: 7475769 [TBL] [Abstract][Full Text] [Related]
52. Anti-HLA antibody analysis and crossmatching in heart and lung transplantation. Reinsmoen NL; Nelson K; Zeevi A Transpl Immunol; 2004; 13(1):63-71. PubMed ID: 15203130 [TBL] [Abstract][Full Text] [Related]
53. HLA matching and its effect on infant and pediatric cardiac graft survival. The Loma Linda Pediatric Cardiac Transplant Team. Alonso de Begona J; Gundry SR; Nehlsen-Cannarella SL; Fullerton DA; Kawauchi M; Razzouk AJ; Vigesaa R; Kanakriyeh M; Boucek M; Bailey LL Transplant Proc; 1991 Feb; 23(1 Pt 2):1139-41. PubMed ID: 1989171 [No Abstract] [Full Text] [Related]
54. HLA histocompatibility affects cardiac transplant rejection and may provide one basis for organ allocation. DiSesa VJ; Kuo PC; Horvath KA; Mudge GH; Collins JJ; Cohn LH Ann Thorac Surg; 1990 Feb; 49(2):220-3; discussion 223-4. PubMed ID: 2306143 [TBL] [Abstract][Full Text] [Related]
55. Impact of HLA-compatibility on rejection sequence and survival rate after orthotopic heart transplantation. Fieguth HG; Wahlers T; Schäfers HJ; Stangel W; Kemnitz J; Haverich A Transplant Proc; 1991 Feb; 23(1 Pt 2):1137-8. PubMed ID: 1989170 [No Abstract] [Full Text] [Related]
56. The University of California at Los Angeles heart transplantation experience. Kobashigawa JA; Laks H; Wu G; Patel J; Moriguchi J; Hamilton M; Fonarow G; Fishbein M; Ardehali A Clin Transpl; 2005; ():173-85. PubMed ID: 17424734 [TBL] [Abstract][Full Text] [Related]
57. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Itescu S; Burke E; Lietz K; John R; Mancini D; Michler R; Rose E; Oz M; Edwards N Circulation; 2002 Mar; 105(10):1214-9. PubMed ID: 11889016 [TBL] [Abstract][Full Text] [Related]